On January 16, 2020 MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), dedicated to the early detection of skin cancer, reported that a total of 5,990,000 stock options have been granted to directors (2,020,000 options), Officers (1,580,000 options) and employees and consultants (2,390,000 options) (Press release, MedX Health, JAN 16, 2020, View Source [SID1234553293]). The options are all exercisable at the price of $0.17 per share, valid for a period to December 31, 2024, and vest immediately. The Company notes that a total of 7,150,000 stock options previously granted in 2014 expired unexercised on November 26, 2019. At this time there are a total of 21,200,000 options available for grant under the Company’s Incentive Stock Option Plan, of which a total of 17,765,000 are currently subject to grants, at a weighted average exercise price of $0.197, and 3,435,000 remain available for grant under the Plan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!